RCM
XLRN

Riverhead Capital Management’s Acceleron Pharma XLRN Stock Holding History

Riverhead Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-331
Closed -$15K – 1538
2019
Q1 		$15K Sell
331
-19
-5% -$834 ﹤0.01% 1481
2018
Q4 		$15K Sell
350
-489
-58% -$24.4K ﹤0.01% 1475
2018
Q3 		$48K Buy
839
+8
+1% +$393 ﹤0.01% 1496
2018
Q2 		$40K Buy
831
+665
+401% +$24.2K ﹤0.01% 1488
2018
Q1 		$6K Buy
+166
New +$7.06K ﹤0.01% 1533

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Riverhead Capital Management's XLRN Position: Q2 2019 in Review

Riverhead Capital Management sold out of Acceleron Pharma (XLRN) in Q2 2019, closing a stake of 331 shares — an estimated $15K sold.

Riverhead Capital Management first reported a position in XLRN in Q1 2018 and held it in 5 quarters. The position peaked at $48K in Q3 2018. 166 funds tracked by Wall St. Rank hold XLRN as of Q2 2019.

  • Riverhead Capital Management reported no remaining Acceleron Pharma position as of Q2 2019 after selling out during the quarter.
  • Riverhead Capital Management sold 331 Acceleron Pharma shares in Q2 2019, an estimated $15K.
  • Riverhead Capital Management first reported a position in Acceleron Pharma in Q1 2018 and held it in 5 quarters.
  • Riverhead Capital Management's Acceleron Pharma position peaked at $48K in Q3 2018.
  • 166 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2019.

Based on Riverhead Capital Management's 13F filing for Q2 2019, filed 12 Aug 2019.